HER2 Biomarkers
Lynparza Benefit in Early BRCA-Mutated Breast Cancer Reignites Universal Genetic Testing Discussion
Premium
The OlympiA trial showed a disease-free survival benefit with adjuvant PARP inhibitor therapy for early-stage, BRCA1/2-mutated, HER2-negative breast cancer patients.
Breast Cancer Immunotherapy Response Markers Emerge From Single-Cell Sequencing Study
Researchers identified several pre-treatment markers that correlated with T-cell expansion and could be predictive of response to a PD1 inhibitor.
Theralink Partners With George Mason, Rutgers Cancer Institute on Breast Cancer Test
The test, developed at George Mason, measures HER2 activation in a breast cancer biopsy to help determine if a patient will respond to treatment.
Hummingbird Biosciences, Tempus Partner to ID Cancer Patients for Anti-HER3 Treatment Trial
The collaboration, through which Hummingbird will have access to Tempus' TIME Trial Network, is focused on advancing the HER3-targeted agent, HMBD-001.
Reveal Genomics plans to have assays available within three years, and is eager to partner with pharmaceutical and diagnostics companies to fulfill its vision.